Ovid Therapeutics (OVID) Total Liabilities (2016 - 2026)

Ovid Therapeutics' Total Liabilities history runs 11 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• Quarterly Total Liabilities rose 22.26% year-over-year to $27.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.4 million (up 22.26% YoY) and the FY2025 annual result came in at $20.3 million, down 15.32% from the prior year.
• Total Liabilities was $27.4 million for Q1 2026 at Ovid Therapeutics, up from $20.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $56.2 million in Q4 2023 and bottomed at $19.2 million in Q3 2025.
• A 5-year average of $27.6 million and a median of $23.9 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities surged 144.55% — and 2025, when it slumped 58.04%.
• Ovid Therapeutics' Total Liabilities stood at $23.0 million in 2022, then jumped by 144.55% to $56.2 million in 2023, then plunged by 57.42% to $23.9 million in 2024, then slipped by 15.32% to $20.3 million in 2025, then soared by 34.95% to $27.4 million in 2026.
• Business Quant data shows OVID's Total Liabilities at $27.4 million in Q1 2026, $20.3 million in Q4 2025, and $19.2 million in Q3 2025.